Prostate Cancer Trial, Recruiting NCT06804785 Sponsor: Northwestern University Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06804785
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a PSA level between 4.0 and 10.0 ng/ml, or an abnormal prostate exam with a PSA level between 2.0 and 10.0 ng/ml, as shown in their lab results.
  • People who have never had a prostate biopsy before, confirmed by their own report or medical records.
  • Men aged 18 to 89 years old.
  • People whose doctor (the principal investigator) has determined they have a life expectancy of at least 10 years.
  • People whose medical records show they are able to carry out daily activities with little to no limitation (known as an ECOG performance status of 0–2 — confirm with trial site if unsure what this means).

Who may not be able to join:

  • People who have taken a type of medication called a 5-alpha-reductase inhibitor within the 12 months before enrolling, as shown in their medical records.
  • People who have had a prostate infection within 1 month before enrolling, as confirmed by medical records.
  • People who are currently receiving or have previously received any prostate cancer treatment, such as hormone therapy, surgery, radiation, or experimental drugs, as recorded in their medical records.
  • People who have had an invasive urological procedure within 1 month before enrolling, as confirmed by medical records and their own report.
  • People for whom the urologist determines a transrectal ultrasound (an internal scan via the rectum) cannot be performed.
  • People who have a medical reason why they cannot have an MRI scan.
  • People who are currently in prison, or men older than 89 years of age.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 240.760.6112

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants with detection of clinically significant prostate cancer (csPCa)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov